ALTEOGEN Inc. 196170

RAHWAY, N.J., September 21, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous use for all indications approved in Japan for KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. In Japan, KEYJECT®, for subcutaneous injection is the planned trademark for KEYTRUDA QLEX. KEYJECT can be administer

Novartis (SWX:NOVN) is back in focus after reporting positive Phase III REMODEL-1 and REMODEL-2 results for its oral BTK inhibitor remibrutinib in relapsing multiple sclerosis, supporting planned global regulatory filings. At a share price of CHF131.32, Novartis has seen building momentum, with a 7 day share price return of 5.36% and a 90 day share price return of 11.31%. Total shareholder return sits at 30.21% over one year and 108.91% over five years, helped recently by the remibrutinib...

The agreement includes option exercise fees, milestone payments, and royalties on net sales of products commercialised with ALT-B4 technology.

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State

Alteogen's platform can turn intravenous biologics into injections, but payments depend on multiple products reaching milestones.